At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 492 enrolled
Drug / intervention
GSK372475 +2 moredrug
Likely dose
GSK372475 1.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Ten-week, Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Paralleled-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating GSK372475, Paroxetine, and 1 other intervention for Depressive Disorder. Completed, enrolled 492 participants across 33 sites in 10 countries.
Detailed Summary
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder
CountriesBulgaria, Canada, Chile, Costa Rica, Croatia, France, Germany, India, Italy, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedJan 2007
Primary CompletionJun 2008
Study CompletionOct 2008
TodayJul 2026
First PostedJan 11, 2007
Enrollment StartDec 19, 2006
Primary CompletionJun 1, 2008
Study CompletionOct 15, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.5 years ago
Interventions
GSK372475drug
GSK372475 1.0-1.5 mg/day
Paroxetinedrug
Paroxetine 20-30 mg/day
Placeboother
Placebo to Match